An industry perspective on drug target validation
Lyn H. Jones · Expert Opinion on Drug Discovery · 2016
Drug attrition in clinical trials due to inadequate preclinical target validation is a huge problem facing drug discovery. The issue is compounded by concerns over the reproducibility of published ...